Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026

Impact · against what's priced in

The announcement of a class action lawsuit against Unicycive Therapeutics (UNCY) introduces potential new legal liabilities and balance sheet risks. While the underlying FDA manufacturing deficiencies that triggered the suit are already reflected in the stock's prior collapse, the legal proceedings create a new, independent headwind.

UNCY−0.30

No priced-in read yet